


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the February 2014 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 1,792)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with breast cancer? (n = 1,792)




Q2. For patients with breast cancer who receive neoadjuvant therapy in your practice and do not achieve pathological complete response (pCR), do you administer additional adjuvant chemo-combination treatment? (n = 1,233)




Q2. For patients with breast cancer who receive neoadjuvant therapy in your practice and do not achieve pathological complete response (pCR), do you administer additional adjuvant chemo-combination treatment?


By Geography



Q2. For patients with breast cancer who receive neoadjuvant therapy in your practice and do not achieve pathological complete response (pCR), do you administer additional adjuvant chemo-combination treatment?




Q2. For patients with breast cancer who receive neoadjuvant therapy in your practice and do not achieve pathological complete response (pCR), do you administer additional adjuvant chemo-combination treatment?




Q2. For patients with breast cancer who receive neoadjuvant therapy in your practice and do not achieve pathological complete response (pCR), do you administer additional adjuvant chemo-combination treatment?

By Specialty



Results: February 2014
BREAST CANCER


Q3. For your patients with recurrent or metastatic breast cancer, please tell us if you typically initiate the following assessments prior to treatment:



Q3. For your patients with recurrent or metastatic breast cancer, please tell us if you typically initiate the following assessments prior to treatment:

By Geography


■ Yes
■ No



Q3. For your patients with recurrent or metastatic breast cancer, please tell us if you typically initiate the following assessments prior to treatment:

By Practice Size


■ Yes
■ No



Q3. For your patients with recurrent or metastatic breast cancer, please tell us if you typically initiate the following assessments prior to treatment:

By Practice Setting


■ Yes
■ No




Q3. For your patients with recurrent or metastatic breast cancer, please tell us if you typically initiate the following assessments prior to treatment:

By Specialty

Yes
No




Q4. What is your preferred order of treatment for HER2-positive/Hormone Receptor-negative metastatic breast cancer? (Please select one per row)



Q4. What is your preferred order of treatment for HER2-positive/Hormone Receptor-negative metastatic breast cancer? (Please select one per row)



By Geography

- First Line
- Second Line
- Third Line and Above





Q4. What is your preferred order of treatment for HER2-positive/Hormone Receptor-negative metastatic breast cancer? (Please select one per row)

By Practice Size





Q4. What is your preferred order of treatment for HER2-positive/Hormone Receptor-negative metastatic breast cancer? (Please select one per row)

By Practice Setting




Q4. What is your preferred order of treatment for HER2-positive/Hormone Receptor-negative metastatic breast cancer? (Please select one per row)

By Specialty




**Q5. Select your preferred first line regimens for treating patients with HER2+/
Hormone Receptor+ metastatic breast cancer: (Please select one per row)**



**Q5. Select your preferred first line regimens for treating patients with HER2+/
Hormone Receptor+ metastatic breast cancer: (Please select one per row)**

By Geography


- Soft tissue disease only
- Visceral disease (bone only)
- Visceral disease (liver or lung or other non-bone lesions)



**Q5. Select your preferred first line regimens for treating patients with HER2+/
Hormone Receptor+ metastatic breast cancer: (Please select one per row)**

By Practice Size


- Soft tissue disease only
- Visceral disease (bone only)
- Visceral disease (liver or lung or other non-bone lesions)



**Q5. Select your preferred first line regimens for treating patients with HER2+/
Hormone Receptor+ metastatic breast cancer: (Please select one per row)**

By Practice Setting


- Soft tissue disease only
- Visceral disease (bone only)
- Visceral disease (liver or lung or other non-bone lesions)



**Q5. Select your preferred first line regimens for treating patients with HER2+/
Hormone Receptor+ metastatic breast cancer: (Please select one per row)**

By Specialty

- Soft tissue disease only
- Visceral disease (bone only)
- Visceral disease (liver or lung or other non-bone lesions)



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.